The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica
Open accessAbstract
Objective: The serum of most neuromyelitis optica (NMO) patients contains autoantibodies (NMO‐IgGs) directed against the aquaporin‐4 (AQP4) water channel located on astrocyte foot processes in the perivessel and subpial areas of the brain. Our objectives were to determine the source of central nervous system (CNS) NMO‐IgGs and their role in disease pathogenesis. Methods: Fluorescence‐activated cell sorting and single‐cell reverse transcriptase polymerase chain reaction were used to identify overrepresented plasma cell immunoglobulin (Ig) sequences in the cerebrospinal fluid (CSF) of an NMO patient after a first clinical attack. Monoclonal recombinant antibodies (rAbs) were generated from the paired heavy and light chain sequences and tested for target specificity and Fc effector function. The effect of CSF rAbs on CNS immunopathology was investigated by delivering single rAbs to rats with experimental autoimmune encephalomyelitis (EAE). Results: Repertoire analysis revealed a dynamic, clonally expanded plasma cell population with features of an antigen‐targeted response. Using multiple independent assays, 6 of 11 rAbs generated from CSF plasma cell clones specifically bound to AQP4. AQP4‐specific rAbs recognized conformational epitopes and mediated both AQP4‐directed antibody‐dependent cellular cytotoxicity and complement‐mediated lysis. When administered to rats with EAE, an AQP4‐specific NMO CSF rAb induced NMO immunopathology: perivascular astrocyte depletion, myelinolysis, and complement and Ig deposition. Interpretation: Molecular characterization of the CSF plasma cell repertoire in an early NMO patient demonstrates that AQP4‐specfic Ig is synthesized intrathecally at disease onset and directly contributes to CNS pathology. AQP4 is now the first confirmed antigenic target in human demyelinating disease. Ann Neurol 2009;66:617–629
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239 · cited 5×
“The titration curves of the AQP4specific rAbs, serum, and CSF on the LN18AQP4 cell line were congruent (Fig 2C), indicating that the CSF plasma cell rAbs had similar binding affinity to serum and CSF NMO-IgG.”
BackgroundMethodInfluentialRevised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
Lucchinetti, C. F. (2002) · Brain · doi:10.1093/brain/awf151 · Cited by 1,210
Roemer, S. F., Parisi, J. E., Lennon, V. A., Benarroch, E. E., Lassmann, H., Bruck, W., Mandler, R. N., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., et al. (2007) · Brain · doi:10.1093/brain/awl371 · Cited by 716
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre
Takahashi, T., Fujihara, K., Nakashima, I., Misu, T., Miyazawa, I., Nakamura, M., Watanabe, S., Shiga, Y., Kanaoka, C., Fujimori, J., et al. (2007) · Brain · doi:10.1093/brain/awm062 · Cited by 633
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica
Hinson, S. R., Pittock, S. J., Lucchinetti, C. F., Roemer, S. F., Fryer, J. P., Kryzer, T. J., & Lennon, V. A. (2007) · Neurology · doi:10.1212/01.wnl.0000289761.64862.ce · Cited by 494
The human immunoglobulin VH repertoire
Cook, G. P., & Tomlinson, I. M. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80166-9 · Cited by 436
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
Jarius, S., Aboul-Enein, F., Waters, P., Kuenz, B., Hauser, A., Berger, T., Lang, W., Reindl, M., Vincent, A., & Kristoferitsch, W. (2008) · Brain · doi:10.1093/brain/awn240 · Cited by 435
Cited by
Jarius, S., Ruprecht, K., Wildemann, B., Kuempfel, T., Ringelstein, M., Geis, C., Kleiter, I., Kleinschnitz, C., Berthele, A., Brettschneider, J., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-14 · Cited by 764
Self-citationCree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Self-citationAquaporin water channels in the nervous system
Papadopoulos, M. C., & Verkman, A. S. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3468 · Cited by 741
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Aquaporin 4 and neuromyelitis optica
Papadopoulos, M. C., & Verkman, A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70133-3 · Cited by 597
Neuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo
Bradl, M., Misu, T., Takahashi, T., Watanabe, M., Mader, S., Reindl, M., Adzemovic, M., Bauer, J., Berger, T., Fujihara, K., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21837 · Cited by 563
Saadoun, S., Waters, P., Bell, B. A., Vincent, A., Verkman, A. S., & Papadopoulos, M. C. (2010) · Brain · doi:10.1093/brain/awp309 · Cited by 548
Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays
Waters, P. J., McKeon, A., Leite, M. I., Rajasekharan, S., Lennon, V. A., Villalobos, A., Palace, J., Mandrekar, J. N., Vincent, A., Bar-Or, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318248dec1 · Cited by 526
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 474
EFNS guidelines on diagnosis and management of neuromyelitis optica
Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illes, Z., Montalban, X., Du Pasquier, R. A., Polman, C. H., Sorensen, P. S., & Hemmer, B. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03066.x · Cited by 461
Self-citationMader, S., Gredler, V., Schanda, K., Rostasy, K., Dujmovic, I., Pfaller, K., Lutterotti, A., Jarius, S., Di Pauli, F., Kuenz, B., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-184 · Cited by 449
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance
Jarius, S., & Wildemann, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.72 · Cited by 423
The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica
Lucchinetti, C. F., Guo, Y., Popescu, B. F. G., Fujihara, K., Itoyama, Y., & Misu, T. (2014) · Brain Pathology · doi:10.1111/bpa.12099 · Cited by 414
Aquaporins in Clinical Medicine
Verkman, A. S. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-043010-193843 · Cited by 388
The spectrum of MOG autoantibody-associated demyelinating diseases
Reindl, M., Di Pauli, F., Rostásy, K., & Berger, T. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.118 · Cited by 375
Jarius, S., Paul, F., Franciotta, D., Ruprecht, K., Ringelstein, M., Bergamaschi, R., Rommer, P., Kleiter, I., Stich, O., Reuss, R., et al. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.03.038 · Cited by 361
“Subsequently, the demonstration of both NMO-like CNS lesions and clinical disease following passive transfer of AQP4-Ab-positive sera in several independent animal studies provided strong evidence for a pathogenic role of AQP4-Ab in vivo [6–12].”
BackgroundSankowski, R., Mader, S., & Valdés-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
Varrin‐Doyer, M., Spencer, C. M., Schulze‐Topphoff, U., Nelson, P. A., Stroud, R. M., C. Cree, B. A., & Zamvil, S. S. (2012) · Annals of Neurology · doi:10.1002/ana.23651 · Cited by 341
Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis
Srivastava, R., Aslam, M., Kalluri, S. R., Schirmer, L., Buck, D., Tackenberg, B., Rothhammer, V., Chan, A., Gold, R., Berthele, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110740 · Cited by 343
Self-citationB cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12271 · Cited by 342
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Carnero Contentti, E., & Correale, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 338
Brilot, F., Dale, R. C., Selter, R. C., Grummel, V., Reddy Kalluri, S., Aslam, M., Busch, V., Zhou, D., Cepok, S., & Hemmer, B. (2009) · Annals of Neurology · doi:10.1002/ana.21916 · Cited by 322
Self-citationAutoantibodies in neurological disease
Prüss, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00543-w · Cited by 319
Weber, M. S., Prod'homme, T., Patarroyo, J. C., Molnarfi, N., Karnezis, T., Lehmann‐Horn, K., Danilenko, D. M., Eastham‐Anderson, J., Slavin, A. J., Linington, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22081 · Cited by 318
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H. L., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
Self-citationKim, S.-H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease
Mader, S., & Brimberg, L. (2019) · Cells · doi:10.3390/cells8020090 · Cited by 293
Neurodegeneration in multiple sclerosis and neuromyelitis optica
Kawachi, I., & Lassmann, H. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313300 · Cited by 283
Inflammation, demyelination, and degeneration — Recent insights from MS pathology
Stadelmann, C., Wegner, C., & Brück, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.007 · Cited by 276
Self-citationZamvil, S. S., & Slavin, A. J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000062 · Cited by 276
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.141 · Cited by 262
Self-citationAquaporin 4: a player in cerebral edema and neuroinflammation
Fukuda, A. M., & Badaut, J. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-279 · Cited by 262
Treatment of neuromyelitis optica: review and recommendations
Kimbrough, D. J., Fujihara, K., Jacob, A., Lana-Peixoto, M. A., Isabel Leite, M., Levy, M., Marignier, R., Nakashima, I., Palace, J., de Seze, J., et al. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2012.06.002 · Cited by 260
Jarius, S., & Wildemann, B. (2013) · Brain Pathology · doi:10.1111/bpa.12084 · Cited by 254
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
Fujihara, K., Bennett, J. L., de Seze, J., Haramura, M., Kleiter, I., Weinshenker, B. G., Kang, D., Mughal, T., & Yamamura, T. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000841 · Cited by 253
Self-citationAnti–Aquaporin‐4 monoclonal antibody blocker therapy for neuromyelitis optica
Tradtrantip, L., Zhang, H., Saadoun, S., Phuan, P., Lam, C., Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2012) · Annals of Neurology · doi:10.1002/ana.22657 · Cited by 253
Self-citationThe clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes
Sellner, J., Hemmer, B., & Mühlau, M. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.013 · Cited by 142
Self-citationLoss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases
Weil, M.-T., Möbius, W., Winkler, A., Ruhwedel, T., Wrzos, C., Romanelli, E., Bennett, J. L., Enz, L., Goebels, N., Nave, K.-A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.008 · Cited by 142
Self-citationPathogenic T cell responses against aquaporin 4
Pohl, M., Fischer, M.-T., Mader, S., Schanda, K., Kitic, M., Sharma, R., Wimmer, I., Misu, T., Fujihara, K., Reindl, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0824-0 · Cited by 98
“cells and demyelinating anti-MOG antibodies [21] as well as in transfer experiments with human NMO-IgG [3, 5] that pathogenic antibodies induce lesions, when reaching the CNS at sites of T cell mediated inflammation.”
BackgroundImmunology of neuromyelitis optica: a T cell-B cell collaboration
Mitsdoerffer, M., Kuchroo, V., & Korn, T. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12118 · Cited by 91
Experimental models of multiple sclerosis
Pachner, A. R. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328346c226 · Cited by 90
Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica
Tradtrantip, L., Yao, X., Su, T., Smith, A. J., & Verkman, A. S. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1734-6 · Cited by 65
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica
Jones, M. V., Huang, H., Calabresi, P. A., & Levy, M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0207-1 · Cited by 56
“Several previous mouse and rat models of NMO focused on the role of the circulating anti-AQP4 antibody in disease pathogenesis concluded that the antibody by itself is insufficient to induce disease, but can exacerbate an experimental autoimmune encephalomyelitis induced by myelin-reactive T cells [4–8].”
The contribution of neuropathology to multiple sclerosis research
Lassmann, H. (2022) · European Journal of Neurology · doi:10.1111/ene.15360 · Cited by 55
Neuromyelitis optica and neuromyelitis optica spectrum disorders
Marignier, R., Cobo Calvo, A., & Vukusic, S. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000455 · Cited by 45
T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO)
Vaknin-Dembinsky, A., Brill, L., Kassis, I., Petrou, P., Ovadia, H., Ben-Hur, T., Abramsky, O., & Karussis, D. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.12.004 · Cited by 39
Deletional tolerance prevents AQP4‐directed autoimmunity in mice
Vogel, A., Knier, B., Lammens, K., Kalluri, S. R., Kuhlmann, T., Bennett, J. L., & Korn, T. (2017) · European Journal of Immunology · doi:10.1002/eji.201646855 · Cited by 34
Self-citationHofer, L. S., Ramberger, M., Gredler, V., Pescoller, A. S., Rostásy, K., Sospedra, M., Hegen, H., Berger, T., Lutterotti, A., & Reindl, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01188 · Cited by 30
T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity
Sagan, S. A., Moinfar, Z., Moseley, C. E., Dandekar, R., Spencer, C. M., Verkman, A. S., Ottersen, O. P., Sobel, R. A., Sidney, J., Sette, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306572120 · Cited by 25
Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica
Liu, Y., Harlow, D. E., Given, K. S., Owens, G. P., Macklin, W. B., & Bennett, J. L. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0767-4 · Cited by 17
Self-citationStructural basis of aquaporin-4 autoantibody binding in neuromyelitis optica
Gupta, M., Khandelwal, N. K., Nelson, A., Hwang, P., Pourmal, S., Bennett, J. L., & Stroud, R. M. (2025) · Science Advances · doi:10.1126/sciadv.adq7560 · Cited by 11
Self-citation
Metadata
- Authors
- Bennett, J. L., Lam, C., Kalluri, S. R., Saikali, P., Bautista, K., Dupree, C., Glogowska, M., Case, D., Antel, J. P., Owens, G. P., Gilden, D., Nessler, S., Stadelmann, C., & Hemmer, B.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-11
- Volume
- 66
- Issue
- 5
- Pages
- 617-629
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2077427574
- Cited by
- 590
- References
- 21
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.